CSL Limited (ASX: CSL; USOTC: CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it is expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. While some antitrust authorities have approved the transaction, some approvals are still outstanding.
Delays in the regulatory approval process are not unusual. CSL and Vifor Pharma are continuing to work closely with the respective remaining competition authorities in their review of the tender offer. CSL and Vifor Pharma expect to provide an update to shareholders and investors as soon as there is more clarity on the timeline.
An exact closing and settlement date will be communicated once all regulatory approvals have been received. CSL remains confident of completing its acquisition of Vifor Pharma AG.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.